Loading stock data…
$30.98-1.14 (-3.55%)
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Immunocore Holdings plc in the Healthcare sector is trading at $30.98 with a market capitalization of $1.7B. Wall Street consensus targets $62.73 (11 analysts), implying a +102.5% move over the next 12 months. The stock is currently 24% below its 52-week high of $40.72, remaining 2.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $115.93M↑ | $106.68M↑ | $104.48M↑ | $103.69M↑ | $97.96M |
| Gross Profit | $114.84M↑ | $106.24M↑ | $101.78M↓ | $103.18M↑ | $96.92M |
| Operating Income | -$3.00M↓ | $7.28M↑ | -$19.69M↓ | -$7.17M↑ | -$14.88M |
| Net Income | -$808,000↓ | $12.97M↑ | -$30.06M↓ | -$177,000↑ | -$10.30M |
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internatio...